Certara Services Archives

Blog

ICER’s Unsupported Drug Price Increase Report: An Analysis

We analyze the drug-price watchdog, ICER’s (Institute for Clinical and Economic Review) “Report on Unsupported…

Ulrich Neumann2019 年 10 月 24 日

On-Demand Webinar

快速跟踪罕见病药物的创新解决方案

This webinar discussed which pharmaceutical payer strategies work and which don't in our rapidly changing…

webdev2019 年 8 月 10 日

Brochure

证据和准入概述

Discover Certara’s holistic approach to market access.

webdev2019 年 5 月 21 日

On-Demand Webinar

使用 RWD 进行高级分析可减轻 AD 药物开发和报销相关的风险

This webinar explained how advanced analytics using real-world data can mitigate challenges in Alzheimer’s disease…

webdev2019 年 5 月 13 日

Blog

Trends for Market Access, HEOR, and Real World Evidence

This blog reviews trends for using health economics and outcomes research and real-world evidence to…

Oliver Leatham2019 年 5 月 10 日

Blog

Real World Evidence Marches Forward in Drug Development

The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm…

Ulrich Neumann2019 年 3 月 20 日

Publication

Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond

Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…

Jieun Choe2018 年 6 月 2 日

Publication

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

webdev2018 年 2 月 15 日

White Paper

药物资产评估：提高交易的 "成功概率”

Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…

webdev2017 年 8 月 24 日

Publication

Abundance of Hepatic Transporters in Caucasians: A Meta-analysis

The aim of this study was to derive quantitative abundance values for key hepatic transporters…

webdev2016 年 10 月 1 日

Certara 服务

ICER’s Unsupported Drug Price Increase Report: An Analysis

快速跟踪罕见病药物的创新解决方案

证据和准入概述

使用 RWD 进行高级分析可减轻 AD 药物开发和报销相关的风险

Trends for Market Access, HEOR, and Real World Evidence

Real World Evidence Marches Forward in Drug Development

Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

药物资产评估：提高交易的 "成功概率”

Abundance of Hepatic Transporters in Caucasians: A Meta-analysis

订阅时事通讯

快捷链接

解决方案

联系我们